Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer

INTRODUCTION: treatments targeting the Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) have improved the natural history of HER2-positive breast cancer. However, except HER2 protein expression and gene amplification, there is no predictive biomarker to guide the HER2-targeted therapies. We dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerin, Mathilde, Gonçalves, Anthony, Toiron, Yves, Baudelet, Emilie, Pophillat, Matthieu, Granjeaud, Samuel, Fourquet, Patrick, Jacot, William, Tarpin, Carole, Sabatier, Renaud, Agavnian, Emilie, Finetti, Pascal, Adelaide, José, Birnbaum, Daniel, Ginestier, Christophe, Charafe-Jauffret, Emmanuelle, Viens, Patrice, Bertucci, François, Borg, Jean-Paul, Camoin, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173470/
https://www.ncbi.nlm.nih.gov/pubmed/30333908
http://dx.doi.org/10.18632/oncotarget.26031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173470/
https://www.ncbi.nlm.nih.gov/pubmed/30333908
http://dx.doi.org/10.18632/oncotarget.26031

Ejemplares similares